Banco de Sabadell S.A lowered its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 47.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,464 shares of the medical research company’s stock after selling 9,336 shares during the quarter. Banco de Sabadell S.A’s holdings in Amgen were worth $1,935,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the business. Kwmg LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $108,000. Braun Bostich & Associates Inc. acquired a new position in shares of Amgen in the 1st quarter valued at $113,000. WealthTrust Fairport LLC acquired a new position in shares of Amgen in the 1st quarter valued at $121,000. Cornerstone Advisors Inc. increased its holdings in shares of Amgen by 76.5% in the 1st quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 316 shares during the period. Finally, Gables Capital Management Inc. acquired a new position in shares of Amgen in the 1st quarter valued at $174,000. 77.20% of the stock is currently owned by institutional investors.
A number of brokerages have recently commented on AMGN. TheStreet raised shares of Amgen from a “c+” rating to a “b-” rating in a report on Friday, May 25th. Royal Bank of Canada reaffirmed a “neutral” rating and issued a $193.00 target price on shares of Amgen in a report on Monday, September 10th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 11th. Piper Jaffray Companies lifted their target price on shares of Amgen from $190.00 to $210.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. They noted that the move was a valuation call. Finally, Cann reaffirmed a “buy” rating and issued a $224.00 target price on shares of Amgen in a report on Monday, July 30th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $202.76.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $195.71, for a total value of $298,457.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.19% of the company’s stock.
Shares of AMGN opened at $200.58 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39. The firm has a market capitalization of $129.13 billion, a price-to-earnings ratio of 15.94, a PEG ratio of 1.94 and a beta of 1.39. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $204.42.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.52 by $0.31. The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $5.73 billion. Amgen had a net margin of 10.19% and a return on equity of 43.18%. Amgen’s revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company posted $3.27 EPS. equities research analysts expect that Amgen, Inc. will post 13.95 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 7th. Shareholders of record on Friday, August 17th were paid a $1.32 dividend. The ex-dividend date of this dividend was Thursday, August 16th. This represents a $5.28 annualized dividend and a yield of 2.63%. Amgen’s dividend payout ratio is currently 41.97%.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Article: Using the New Google Finance Tool
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.